(CercleFinance.com) – Ipsen announced Friday evening the finalization of the agreement under which it acquired all of the outstanding shares of Epizyme at a price of 1.45 dollars per share to which is added a certificate of guaranteed value of a dollar per share, thereby expanding its oncology portfolio.
As part of the transaction, the Frenchman acquires Epizyme’s lead drug, Tazverik, a first-in-class chemotherapy-free EZH2 inhibitor, which has obtained US FDA approval under a fast-track process in 2020.
The laboratory also acquires Epizyme’s oral SETD2 inhibitor drug candidate in development, EZM0414, first in its class, which obtained an accelerated procedure from the FDA in 2021.